Aclaris Therapeutics Stock Forecast, Price & News

-0.17 (-1.13 %)
(As of 08/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume286,295 shs
Average Volume448,038 shs
Market Capitalization$776.96 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ACRS News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Aclaris Therapeutics logo

About Aclaris Therapeutics

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is being developed as a treatment for moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, which is being developed as a treatment for psoriasis and/or inflammatory bowel disease. It also provides contract research services. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.23 out of 5 stars

Medical Sector

303rd out of 1,309 stocks

Pharmaceutical Preparations Industry

144th out of 646 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Aclaris Therapeutics (NASDAQ:ACRS) Frequently Asked Questions

Is Aclaris Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aclaris Therapeutics stock.
View analyst ratings for Aclaris Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Aclaris Therapeutics?

Wall Street analysts have given Aclaris Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aclaris Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Aclaris Therapeutics?

Aclaris Therapeutics saw a decline in short interest in July. As of July 15th, there was short interest totaling 3,510,000 shares, a decline of 13.1% from the June 30th total of 4,040,000 shares. Based on an average trading volume of 758,000 shares, the short-interest ratio is currently 4.6 days. Approximately 7.4% of the company's shares are short sold.
View Aclaris Therapeutics' Short Interest

When is Aclaris Therapeutics' next earnings date?

Aclaris Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Aclaris Therapeutics

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) posted its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.27. The biotechnology company had revenue of $1.78 million for the quarter, compared to the consensus estimate of $1.47 million. Aclaris Therapeutics had a negative net margin of 936.71% and a negative trailing twelve-month return on equity of 107.60%.
View Aclaris Therapeutics' earnings history

How has Aclaris Therapeutics' stock been impacted by COVID-19?

Aclaris Therapeutics' stock was trading at $1.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ACRS stock has increased by 1,306.6% and is now trading at $14.91.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ACRS?

3 brokerages have issued 12-month target prices for Aclaris Therapeutics' stock. Their forecasts range from $32.00 to $32.00. On average, they anticipate Aclaris Therapeutics' share price to reach $32.00 in the next twelve months. This suggests a possible upside of 114.6% from the stock's current price.
View analysts' price targets for Aclaris Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Aclaris Therapeutics' key executives?

Aclaris Therapeutics' management team includes the following people:

What is Neal Walker's approval rating as Aclaris Therapeutics' CEO?

1 employees have rated Aclaris Therapeutics CEO Neal Walker on Neal Walker has an approval rating of 100% among Aclaris Therapeutics' employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Aclaris Therapeutics' key competitors?

What other stocks do shareholders of Aclaris Therapeutics own?

What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Who are Aclaris Therapeutics' major shareholders?

Aclaris Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Asymmetry Capital Management L.P. (0.61%), New York State Common Retirement Fund (0.07%), Alliancebernstein L.P. (0.05%) and Victory Capital Management Inc. (0.03%). Company insiders that own Aclaris Therapeutics stock include David N Gordon, Frank Ruffo, Kamil Ali-Jackson and Neal Walker.
View institutional ownership trends for Aclaris Therapeutics

Which institutional investors are buying Aclaris Therapeutics stock?

ACRS stock was acquired by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P., New York State Common Retirement Fund, Alliancebernstein L.P., and Victory Capital Management Inc..
View insider buying and selling activity for Aclaris Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aclaris Therapeutics' stock price today?

One share of ACRS stock can currently be purchased for approximately $14.91.

How much money does Aclaris Therapeutics make?

Aclaris Therapeutics has a market capitalization of $776.96 million and generates $6.48 million in revenue each year. The biotechnology company earns $-51,010,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.

How many employees does Aclaris Therapeutics have?

Aclaris Therapeutics employs 57 workers across the globe.

What is Aclaris Therapeutics' official website?

The official website for Aclaris Therapeutics is

Where are Aclaris Therapeutics' headquarters?

Aclaris Therapeutics is headquartered at 640 LEE ROAD SUITE 200, WAYNE PA, 19087.

How can I contact Aclaris Therapeutics?

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected]

This page was last updated on 8/4/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.